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Six variants of Japanese encephalitis (JE) virus strain P3 were selected for resistance to binding to mouse brain membrane
receptor preparations (MRP). All but one of these MRP escape (MRPR) variants were significantly attenuated in mice for both
neuroinvasiveness (.200-fold) and neurovirulence (.500-fold) compared to their parent virus. Attenuated mouse brain MRPR
variants could be detected in the sera of mice following either intracerebral (i.c.) or intraperitoneal inoculation, whereas virus
was detected only in brains of mice following ic inoculation. Immunization of mice with MRPRs induced neutralizing antibodies
and protected mice against challenge with wild-type JE virus. A common amino acid mutation was found in the envelope (E)
protein gene of all attenuated mouse brain MRPR variants at residue E-306 compared to P3 virus grown in mosquito C6-36
cells or plaque purified and amplified in monkey kidney Vero cells. This amino acid is putatively responsible for attenuation
due to alteration in binding of JE virus to its cell receptor in mouse brain. The methodology developed in this study has
general applicability to the attenuation of virulence of viruses and to the identification of agents that will block amino acids
in a viral attachment protein(s) that interacts with cell receptors. © 1998 Academic Press
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INTRODUCTION
To date, vaccination is the best approach for reducing
human mortality and morbidity caused by infectious dis-
eases. Vaccines have made significant contributions to
the eradication or the control of several major infectious
diseases in the world, such as smallpox, yellow fever,
poliomyelitis, and measles (WHO, 1980; Chase, 1982;
Monath, 1990). In particular, live attenuated vaccines
have proved to be successful due to stimulation of dif-
ferent arms of the host immune response. Many of these
live vaccines are natural virus variants derived by pas-
saging virus in abnormal hosts, e.g., yellow fever 17D
virus in chicken tissue (Monath, 1990). However, this
method is empirical, not cost-efficient, and it takes a long
time to develop a useful vaccine that can be adminis-
tered to humans, if it can be done at all.
A virus cannot infect a susceptible cell unless its viral
attachment protein can bind to a molecule on the cell
surface which serves as receptor for the particular virus.
The expression of the receptor on specific cells or tis-
sues in the whole host is a major determinant of the
route of virus entry into the host, the pattern of virus
spread in the host, and the resulting pathogenesis
(Lentz, 1990; Norkin, 1995). There are many factors de-
termining host range and tissue tropism of viruses, in-
cluding the nature, number, and distribution of host cell
receptor sites, which may be multivalent and consist of
several receptor units (Paulson, 1985; Mims, 1986).
The genus Flavivirus of the family Flaviviridae (West-
away et al., 1985) includes mosquito- and tick-borne
viruses, such as dengue and Japanese encephalitis (JE).
To date, the only flavivirus cell receptor identified is for
dengue-2 virus. Chen et al. (1997) have reported that the
dengue-2 virus envelope (E) protein interacts with glyco-
saminoglycans on the cell surface.
Japanese encephalitis is a disease caused by JE virus,
which is epidemic throughout Asian countries (Huang,
1982) and the most common epidemic virus encephalitis
in the world. The virus has a tissue tropism for the brain,
in particular neurones, and is highly neurovirulent. We
have used JE virus as a model system for investigating
the flavivirus attachment protein–cell receptor interac-
tion. A novel methodology has been established to select
attenuated virus variants. The aims of the studies pre-
sented were (a) the selection of JE virus variants that
were resistant to binding to mouse brain membrane
receptor preparations (MRPR), (b) the evaluation of the
attenuation of neurovirulence and neuroinvasiveness of
the MRPR variants in mice, and (c) the analysis of the
genetic mutation(s) which may be responsible for the
attenuation of virulence of the MRPR variants. Identifica-
tion of amino acids in the viral attachment protein that
bind to a cell receptor is a potential route to understand-
ing the molecular basis of the cell/tissue tropism of
viruses, the generation of live attenuated vaccines, and
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the design of antiviral agents that interfere with binding
of the viral attachment protein to the cell receptor.
RESULTS
Generation and confirmation of MRPR variants
JE P3 virus grown in mosquito C6-36 cells (P3/C6-36)
was mixed and incubated with either mouse or monkey
brain or monkey liver MRPs in 50 mM Tris buffer, pH 7.6, at
37°C for 30 min. The mixture was pelleted and the super-
natant plaqued as described under Materials and Methods.
It was found that the infectivity of P3 virus was greatly
reduced following incubation with mouse or monkey brain
MRP but not monkey liver MRP (Table 1). No P3/C6-36 virus
infectivity was detectable in the supernatent following in-
cubation with monkey brain MRP. For selection of mouse
brain MRPR variants, P3/C6-36 virus was mixed with excess
mouse brain MRP, which resulted in a 103.6 reduction in
infectivity (Table 2). Three independent plaques from the
virus population of the P3 virus that escaped ‘‘binding’’ to the
mouse brain MRP in Tris pH 7.6 buffer were selected and
each was independently amplified in Vero cells as de-
scribed under Materials and Methods. These were termed
MRPR (pH 7.6) variants.
After plaque purification and amplification in monkey
kidney Vero cells, there was no reduction in infectivity of
any of the three MRPR (pH 7.6) variant viruses following
incubation with fresh mouse brain MRPs (Table 2), which
indicated that they were true MRPR variants. In parallel,
the P3/C6-36 virus used to generate the MRPR variants
was also plaque purified and amplified in Vero cells
(P3/Vero) to determine effects of Vero cell passage on
the phenotype of P3 virus. The infectivity of the P3/Vero
virus was reduced to an extent similar to that of P3/C6-36
virus after incubation with mouse brain MRPs (Table 2).
Pathogenicity of wild-type JE virus strains P3 and its
MRPR (pH 7.6) variants
Groups of outbred NIH-Swiss mice were inoculated by
the ic or ip route with either parental P3/C6-36 or P3/Vero
virus or one of the MRPR (pH 7.6) variants. The PFU/LD50
values and AST 6 SEM were determined. Comparison of
parental P3/C6-36 and P3/Vero viruses showed that
plaque purification and amplification in Vero cells had
little effect on the virulence of P3 virus in terms of LD50
following either ic or ip inoculation, although P3/Vero
virus was slightly less virulent than P3/C6-36 virus (Table
3). In comparison, all three mouse brain MRPR variants
selected in 50 mM Tris buffer, pH 7.6, were attenuated at
least 200-fold compared with the parental P3 virus fol-
lowing ip inoculation (i.e., neuroinvasiveness) (Table 3).
Also, all three mouse brain MRPR (pH 7.6) variants were
significantly attenuated in neurovirulence (at least 500-
fold) compared with their parental viruses after ic inoc-
ulation of mice (Table 3).
Generation of MRPR variants in Tris buffer at pH 7.0
or 5.0
The pH of the Tris buffer used to incubate MRPs
with virus was varied to either pH 7.0 or 5.0 to inves-
tigate the effect of pH on generation of MRPR variants.
MRPR variants were generated using the procedures
described above except that the pH of the Tris buffer
was altered. Subsequently, all variants generated
were demonstrated to be true MRPR variants as de-
TABLE 1
Binding of P3 Virus to Mouse Brain, Monkey Brain, and Monkey
Liver Membrane Receptor Preparations (MRP)
Infectivitya
(log10PFU)
Binding
indexb
Binding
(%)
Buffer 6.1 — —
Mouse brain MRP 2.5 3.6 99.97
Monkey brain MRP ,1.0 .5.1 .99.99
Monkey liver MRP 6.0 0.1 8.33
a Infectivity: infectious virus remaining is the supernatant following
incubation of virus with MRP or buffer and pelleting the virus–MRP
complex as described under Materials and Methods.
b Binding index: log10 infectivity in buffer/infectivity in MRP supernatant.
TABLE 2
Confirmation that P3 Virus Mouse Brain MRPR (pH 7.6) Variant Do Not Bind to Mouse Brain MRPs
Virus strain
Infectivity (log10PFU)
Binding indexa Binding (%)Virus 1 buffer Virus 1 mouse brain MRP
Parents
P3/C6-36 6.1 2.5 3.6 99.97
P3/Vero 7.3 3.6 3.7 99.98
P3 mouse brain variants
MRPRI 5.6 6.0 20.4 NA
MRPRII 6.0 6.6 20.6 NA
MRPRIII 6.7 7.3 20.6 NA
Note. NA, Not applicable.
a Binding index: log10infectivity in buffer/infectivity in MRP supernatant.
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scribed above. The MRPR (pH 5.0) variant was atten-
uated for neurovirulence and neuroinvasiveness to a
degree similar to that of the three variants selected in
Tris buffer at pH 7.6, whereas the MRPR (pH 7.0) variant
was attenuated for neuroinvasiveness but not neuro-
virulence (Table 3). The neurovirulence of the MRPR
(pH 7.0) variant was only 10-fold less than that of the
parental virus and it was 100-fold more virulent than
the other MRPR variants generated in these studies. To
investigate the lack of attenuation of MRPR (pH 7.0)
further, the MRPR I (pH 7.6) variant was incubated with
MRP in Tris buffer, pH 7.0. The resulting variant,
termed MRPR I (pH 7.6 3 7.0), had not reverted to
virulence and was still attenuated for neuroinvasive-
ness and neurovirulence (Table 3).
Determination of infectivity of the MRPR (pH 7.6)
variants following inoculation by the ic and ip routes
Mice were sacrificed on days 2 and 7 after ic inoculation
of 10 PFU or ip inoculation of 1000 PFU of the MRPR (pH 7.6)
variant viruses to determine whether they could be de-
tected in the sera and the brains of mice. All three mouse
brain MRPR (pH 7.6) variants replicated in the infected mice
(Table 4). The infectivity of the MRPR (pH 7.6) variants in the
brains and sera were lower than those of their parental
virus at day 2 post ic inoculation. All mice inoculated by the
ic route with parental P3 virus died by 7 days postinfection.
The infectivity of the MRPR (pH 7.6) variants was signifi-
cantly lower than that of parental virus in the sera at days 2
and 7 post ip inoculation.
TABLE 3
Mouse Neurovirulence of Parent JE P3/C6-36 or P3/Vero Viruses and Mouse Brain MRPR Variants
Following Intracerebral or Intraperitoneal Inoculation
Virus
Route of inoculation
Intraperitoneal
PFU/LD50
Intracerebral
PFU/LD50 AST 6 SEM
a
Parents
P3/C6-36 50 0.0001 6.5 6 0.3
P3/Vero 280 0.0004 6.0 6 0.3
Mouse brain variants
MRPRI (pH 7.6) .50,000 5.6 8.0 6 1.2
MRPRII (pH 7.6) .50,000 0.8 8.0 6 0.6
MRPRIII (pH 7.6) .50,000 10.0 8.6 6 1.0
MRPR (pH 7.0) 35,000 0.005 7.4 6 0.2
MRPR (pH 5.0) 40,000 0.5 7.2 6 0.6
MRPR I/mouse brainb .20,000 0.2 6.6 6 0.2
MRPRI/(pH 7.6 3 7.0)c .80,000 20 NA
Note. NA, not applicable.
a AST 6 SEM: Average survival time 6 standard error of the mean which were calculated from mice inoculated with 10 PFU virus by the ic route.
b MRPR I/mouse brain: MRPRI (pH 7.6) virus-infected mouse brain.
c MRPRI(pH 7.6 3 7.0): MRPRI virus was selected using MRP in pH 7.6 buffer and then was reselected with fresh MRP in pH 7.0 buffer.
TABLE 4
Virus Infectivity of JE Virus Parent P3 and Its MRPR (pH7.6) Variants Following ic or ip Inoculation of Mice
Inoculum
ic ip
Day 2 Day 7 Day 2 Day 7
Brain Sera Brain Sera Brain Sera Brain Sera
Parents
P3/C6-36 6.4 6 0.2a 4.0 6 0.3 NAb NA ,2.0 6.1 6 0.9 3.4 6 0.2 2.8 6 1.0
P3/Vero 5.8 6 0.2 2.9 6 0.2 NA NA ,2.0 5.6 6 0.5 2.9 6 0.5 2.2 6 0.1
Variants
MRPRI 4.2 6 0.5 2.0 6 0.7 2.7 6 0.9 ,2.0 ,2.0 3.0 6 0.4 ,2.0 2.0 6 0.3
MRPRII 4.6 6 0.4 ,2.0 3.1 6 0.3 ,2.0 ,2.0 4.6 6 0.5 ,2.0 2.1 6 0.6
MRPRIII 4.7 6 0.1 2.0 6 0.7 3.0 6 0.6 ,2.0 ,2.0 2.9 6 0.3 ,2.0 ,2.0
a Infectivity expressed as log10PFU/ml (mean 6 SEM); three mice per sample group.
b NA, not available as to mice died from infection.
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Immunogenicity of the MRPR variants
NIH-Swiss mice inoculated with the mouse brain
MRPR (pH 7.6) variants induced neutralizing antibody in
all infected mice by day 15 post ip inoculation (Table 5).
To demonstrate induction of protective immunity, mice
immunized with the MRPR I (pH 7.6) variant were chal-
lenged at 21 days postimmunization with 2000 PFU
(equivalent to 200 LD50) of parental strain P3 by the ic
route. All mock-infected mice (5/5) died, whereas 80%
(4/5) of MRPR I (pH 7.6)-immunized mice survived chal-
lenge.
Comparison of nucleotide and amino acid sequence
changes of the mouse brain MRPR variants with wild-
type parent P3/C6-36 virus and P3/Vero virus
To investigate the genetic differences and the receptor
attachment domain of parental P3 virus and its MRPR
variants, the premembrane (prM), membrane (M), and
envelope E protein genes of P3 viruses and the MRPR
variants were cloned and sequenced. The P3/Vero virus
had 13 nucleotide differences compared with the P3/
C6-36 virus in prM, M, and E protein genes (data not
shown), which resulted in five amino acid changes at
residues E-46, E-129, E-209, E-351, and E-388 (Table 6)
and may be responsible for the reduced virulence of
P3/Vero virus compared to P3/C6-36 virus (Table 3).
Therefore, these amino acid differences cannot be con-
sidered directly responsible for attenuation of the MRPR
variants.
All three mouse brain MRPR (pH 7.6) variants had
identical nucleotide sequences in prM, M, and E protein
genes. They had 23 nucleotide differences compared to
the P3/C6-36 virus and 20 nucleotide differences com-
pared to the P3/Vero virus (data not shown). However,
these mouse brain MRPR variants had only two amino
acid changes compared with both parental P3/C6-36 and
P3/Vero viruses at residues E-306 (G 3 E) and E-408
(L 3 S) (Table 6).
The MRPR (pH 5.0) variant had substitutions at E-202
(Y 3 H) and E-306 (G 3 E), while wild-type P3/C6-36
virus selected at pH 5.0 differed from its progenitor at
one residue: E-129 (A 3 T). The MRPR (pH 7.0) variant
had substitutions at E-212 (L 3 M) and E-222 (A 3 S)
(but not E-306). Generation of the MRPR I (pH 7.6 3 pH
7.0) variant resulted in the MRPR I (pH 7.6) variant accu-
mulating additional substitutions at E-76 (M 3 T), E-77
(T 3 A), and E-227 (P 3 S), while retaining the substi-
tutions at E-306 and E-408. Thus, all the attenuated MRPR
variants share the E-306 (G 3 E) substitution (Table 6).
Reversion to neurovirulence of mouse brain MRPR
variants
The potential of a mouse brain MRPR variant to revert
to a virulent phenotype was investigated by infecting
mice with the MRPR I (pH 7.6) variant by the intracerebral
route and harvesting brain on day 7 postinfection. The
TABLE 5
Serum Neutralization Antibody Titers of Individual Mice Following
Intraperitoneal Inoculation of Mouse Brain MRPR (pH7.6) Escape
Virus Variants
Neutralization antibody titer
MRPRI MRPRII MRPRIII
320 320 .320
160 160 320
160 160 160
40 160 160
Note. Neutralization titer: Taken as the highest dilution of serum to
neutralize 50% of homologous challenge virus.
TABLE 6
Comparison of Amino Acid Changes in the E Protein Sequence of P3/C6-36 or P3/Vero Viruses and Mouse Brain MRPR Variants
Position P3/C6-36 P3/Vero
MRPR mutants
pH 7.6 pH 7.0 pH 5.0 pH 7.6 3 7.0a
E-46 T I T T I T
E-76 M M M M M T
E-77 T T T T T A
E-129 A T T A T T
E-202 Y Y Y Y H Y
E-209 R K K K R K
E-212 L L L M L L
E-222 A A A S A A
E-306 G G E G E E
E-351 A V V G A V
E-388 E G G E E G
E-408 L L S L L S
Note. All three MRPR (pH 7.6) variants were identical in sequence.
a MRPR I (pH 7.6) incubated with fresh MRP at pH 7.0.
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mouse brain material (termed MRPR I/mouse brain virus)
had a 28-fold increase in neurovirulence following ic
inoculation compared to its parent MRPR I (pH 7.6) vari-
ant, but was still 200-fold attenuated compared to P3/
Vero virus (Table 3). Following ip inoculation, MRPR
I/mouse brain virus was attenuated similarly to its parent
MRPR I (pH 7.6) variant virus. The E gene of MRPR
I/mouse brain virus had two nucleotide differences com-
pared to its parent MRPR I (pH 7.6) variant but neither
encoded an amino acid substitution.
DISCUSSION
Virus binding to the host cell surface receptor(s) is the
first step in the virus replication cycle and is directly
involved in the tissue tropism and pathogenesis of many
viruses (Fields and Greene, 1982). Despite their impor-
tance, the identities and host cell functions of relative
few viral cell receptors are known at present or widely
accepted. The only cellular receptor identified for a fla-
vivirus was reported very recently for dengue-2 virus.
Chen et al. (1997) have shown that the dengue-2 virus E
protein binds to glycosaminoglycans on the surface of
monkey kidney Vero cells. Thus, it is assumed from this
and other studies that the E protein of flaviviruses plays
a role in cellular tropism by being the viral attachment
protein involved in virus binding to cellular receptors
(Guirakhoo et al., 1991; Anderson et al., 1992; Heinz et al.,
1994; Marianneau et al., 1996).
Investigation of in vivo cell receptors for viruses is
difficult due to the manipulation of animal tissues and the
inability, for most viruses, to purify sufficient quantities of
the virus to undertake physical binding assays. In this
paper we describe a procedure for generation of variants
that apparently do not bind to MRPs derived from animal
tissues (Tables 1 and 2). As a model we have examined
the reduction of infectivity of JE virus following incubation
with mouse brain MRPs. The specificity of the procedure
was demonstrated by the lack of reduction in infectivity
of neurotropic. JE virus following incubation with monkey
liver MRP (Table 1) and the generation of variants was
confirmed by the failure of mouse brain MRPR variants to
reduce infectivity when incubated with fresh mouse brain
MRP. All three mouse brain MRPR variants generated in
Tris buffer, pH 7.6, were derived from independent plaque
picks from the same parent virus population and were
significantly attenuated for both neuroinvasiveness and
neurovirulence in mice compared with their wild-type
parent strain P3 (Table 3). We have previously demon-
strated that JE virus accumulates a relatively large num-
ber of nucleotide mutations on passage in different cell
types (Cao et al., 1995) and this was seen when strain P3
was passaged from mosquito C6-36 to monkey Vero
cells (Table 6). However, all three MRPR variants derived
in Tris buffer, pH 7.6, which were derived from indepen-
dent plaque picks, had identical sequences and only two
amino acid substitutions, which were not seen in P3
virus that was grown in either C6-36 or Vero cells and
was highly neurovirulent when grown in either cell type
(Table 3). Thus, there were only two amino acid substi-
tutions (at E-306 and E-408) within the E protein which
putatively were involved in the binding of JE virus strain
P3 to cells in the mouse brain. Since these variants were
identical in nucleotide sequence and attenuated pheno-
type, other MRPR variants were generated utilizing dif-
ferent pHs. The MRPR variant derived in Tris buffer, pH
5.0, and the MRPR I (pH 7.6 3 7.0) variant were both
attenuated for neurovirulence, while the MRPR (pH 7.0)
variant was only marginally attenuated. The latter lacked
the substitution at E-306, suggesting that this residue
was important for the phenotypic property of attenuation
of mouse neurovirulence. Also, on the basis of the few
variants studied, decreasing the pH appeared to select
for viruses with mutations between E-191 and E-227 (see
Table 6), suggesting that this region of the JE virus E
protein is susceptible to changes in pH. Examination of
the 3-D structure of the E protein (Rey et al., 1995)
predicts that these amino acids are in domain II, which is
associated with dimerization.
JE virus strain P3 was selected for these studies due to
its very low PFU/LD50 (0.0001 PFU by the ic route),
whereas most JE strains have PFU/LD50 values around
0.1 PFU by the ic route (Ni and Barrett, 1996). The amino
acid substitution found in the E protein at E-306 was
shared by all the MRPR variants attenuated for neuroviru-
lence (Table 3). However, the attenuated phenotype of
the MRPR (pH 7.0) variant for neuroinvasiveness indi-
cates that E-306 is probably not associated with the
neuroinvasive phenotype. Thus, E-306 is proposed to be
involved in the binding of JE virus strain P3 E protein with
its cell receptor in mouse brain. Residue E-306 is a G in
P3 virus, while it was E in the mouse brain MRPR vari-
ants. Significantly, examination of genetic databases re-
veals that there are 50 JE virus E protein sequences and
all have the residue E at E-306. Thus, mutation of strain
P3 at residue E-306 gives rise to a residue found in all
other JE virus strains that have been sequenced. Also,
the neurovirulence phenotype of the mouse brain MRPR
variants is similar to that of other wild-type strains of JE
virus (Ni and Barrett, 1996).
Mapping of the amino acid substitution E-306 onto the
proposed model of the three-dimensional structure of the
ectodomain of the E protein of tick-borne encephalitis
(TBE) virus (Rey et al., 1995), a flavivirus related to JE
virus, revealed that E-306 is in domain III, which has
been associated with mouse neuroinvasiveness of JE
and other flaviviruses, and proposed by Rey et al. (1995)
to include a virus attachment site that interacts with a
cellular receptor(s) [JE (Cecilia and Gould, 1991; Hase-
gawa et al., 1992), louping ill (Jiang et al., 1993; Gao et al.,
1994), TBE (Holzmann et al., 1989) and dengue-2 viruses
(Hiramatsu et al., 1996; Sanchez and Ruiz, 1996)]. Inter-
estingly, a mutation at E-308 of louping ill virus (equiva-
lent to E-305 for JE virus) attenuated neuroinvasiveness
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but not neurovirulence of louping ill virus (Jiang et al., 1993).
Finally, Chen et al. (1997) have recently speculated that
flaviviruses bind to glycosaminoglycans (GAGs) on the sur-
face of cells and proposed a region between E-284 and
E-310 as being a putative GAG-binding motif. The mutation
identified in this study at residue E-306 is consistent with
the proposal of Chen et al. (1997). However, there is no
experimental evidence to support the interaction of the JE
virus E protein with GAGs, especially as the studies of Chen
et al. (1997) are based on the interaction of dengue-2 virus
E protein with Vero cells.
Although the MRPR variants had been selected using
mouse brain, the variants had reduced virulence for mice
following ic inoculation but were not completely attenu-
ated. We have three possible explanations. First, the
procedure to generate the mouse brain MRPs causes a
conformational change in the cell attachment protein in
the MRP such that virus does not bind to the in vivo cell
receptor in the correct conformation. Second, JE virus
may utilize more than one cell receptor. This proposal is
supported by the ability of MRPR variants to plaque and
grow in monkey kidney Vero cells in a manner indistin-
guishable from that of the parental virus. Alternatively, a
combination of conformational changes and the ability of
JE virus to utilize different cell receptors may be respon-
sible for the alternated phenotype of the MRPR variants.
The present study demonstrated that JE virus mouse
brain MRPR variants can be readily selected in vitro from
parental virus in the presence of an excess amount of
MRP and have an attenuated phenotype in mice. This
study suggests that selection of MRPR variants from a
target tissue of the virus in vivo is one potential route for
generating attenuated virus strains. Furthermore, it may
be possible to generate attenuated variants with multiple
mutations by selection using MRPs from different tissues
consecutively. Further studies with JE or other viruses
along the line presented in this paper may ultimately
lead to the rapid selection and development of a rela-
tively cheap virus vaccine candidate(s). Finally, identifi-
cation of amino acids involved in the virus attachment
domain may aid in the design of antiviral agents that
interfere with the binding of virus to cell receptors.
MATERIALS AND METHODS
Viruses and cells
Wild-type JE virus strain P3 virus was kindly provided by
Dr. Robert Shope of the Yale Arbovirus Research Unit.
Monkey kidney (Vero) cell and Aedes albopictus mosquito
C6-36 cells were grown at 37° and 28°C, respectively, in
Eagle’s minimal essential medium (EMEM; Sigma) supple-
mented with 10% heat-inactivated fetal calf serum (FCS;
Sigma), 2 mM L-glutamine (Sigma), and antibiotics.
Membrane receptor preparations
Mouse brains were collected from 3- to 4-week-old
female Balb/C mice. Monkey liver and monkey brain
were obtained from a cynomolgus monkey. The mem-
brane receptor preparations (MRPs) were made based
on the method described for neurotransmitter receptor
binding assays ((Middlemiss and Frozard, 1983). The
tissues were rapidly dissected, weighed, and homoge-
nized in Tris buffer (50 mM, pH 7.6). The homogenate was
centrifuged (35,600 g for 10 min), the pellet resuspended
in the same volume of Tris buffer, and the process re-
peated twice. Between the second and third centrifuga-
tions, the homogenate was incubated at 37°C for 10 min.
The final pellet was resuspended in a volume of Tris
buffer (50 mM, pH 7.6) to give a final protein concentra-
tion of approximately 20–40 mg wet brain/ml and stored
at 270°C. For some experiments the MRPs were resus-
pended in 50 mM Tris buffer at pH 7.0 or pH 5.0.
Generation of virus mouse brain MRP escape (MRPR)
variants
Prior to use, an aliquot(s) of frozen MRPs and virus
stock was removed from 270°C, rapidly thawed at 37°C,
and kept on ice. A 100-ml aliquot of neat virus stock was
added to 900 ml of the mouse brain MRPs containing
excess membrane receptor(s) and vortexed to mix. Con-
trol virus samples were prepared in the same way but
mixed with 900 ml of Tris buffer (50 mM Tris, pH 7.6)
instead of MRP. For some experiments Tris buffer at pH
7.0 or at pH 5.0 was used. Samples were incubated at
37°C for 30 min on a rotating stand. After incubation, the
virus–MRP suspension and control virus–Tris buffer
samples were centrifuged at 13,000 rpm for 10 min to
remove the membrane material and bound virus. Resid-
ual virus infectivity in the supernatant was determined by
infecting Vero cell monolayers and counting plaques
produced after 5 days incubation at 37°C. Individual
MRP-resistant (MRPR) variant plaques were picked and
amplified in Vero cells. The virus variants generated
were investigated for binding to fresh MRPs. Lack of
reduction in infectivity following incubation of the virus
variants with fresh mouse brain MRP confirmed that they
were true MRPR variants.
Mouse pathogenicity studies
NIH-Swiss female outbred white mice, 3 to 4 weeks
old, were obtained from Harlan (Indianapolis, IN). The
mice were inoculated with either 20 ml of virus diluted in
PBS by the intracerebral (ic) route or 100 ml by the
intraperitoneal (ip) route. Virulence studies involved eight
mice per dose group, and LD50 and average survival time
(AST) values were determined. Mice examined for infec-
tivity were sacrificed at day 2 or day 7 post ic or ip
inoculation and the brains and sera were processed for
infectivity titration by plaque assays.
Immunogenicity and protection studies
NIH-Swiss female outbred white mice, 3 to 4 weeks
old, were obtained from Harlan (Indianapolis, IN). Four
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mice for each MRPR variant were inoculated with 103
PFU virus by the ip route. Mice were sacrificed on day 15
postinoculation and blood was collected by cardiac
puncture. The serum fraction was collected and stored at
220°C. Neutralization assays were performed as de-
scribed by Wills et al. (1992). To examine protective
immunity, groups of five mice were immunized with 1000
PFU MRPR I (pH 7.6) variant or mock-immunized by the ip
route and challenged at 21 days postimmunization with
2000 PFU (equivalent to 200 LD50 in 7- to 8-week-old
mice) of strain P3/C6-36 by the intracerebral route.
Sequencing and analyzing the genome of virus RNAs
RT–PCR, cloning, and sequencing virus RNA were as
described before (Ni et al., 1994). Computer analyses of
nucleic acid data and deduced amino acid sequences
were accomplished using the MICROGENIE (Queen and
Korn, 1984), PCGENE, and Genetic Computer Group (De-
vereux et al., 1984) programs.
ACKNOWLEDGMENTS
Haolin Ni was supported by the James W. McLaughlin Fellowship
fund. This work was conducted, in part, by the Clayton Foundation for
Research. We thank Drs. Phil Minor, Frank Taffs, and David Wood of the
National Institute of Biological Standards and Control (UK) for provision
of tissues from the cynomolgus monkey.
REFERENCES
Anderson, R., King, A. D. and Innis, B. L. (1992). Correlation of E protein
binding with cell suceptibility to dengue 4 virus infection. J. Gen. Virol.
73, 2155–2159.
Cao, J. X., Ni, H., Sil, B. K., Ryman, K. D., and Barrett, A. D. T. (1995).
Passage of Japanese encephalitis virus in HeLa cells results in
mutations in the structural protein genes and attenuation of virulence
in mice. J. Gen. Virol. 76, 2757–2764.
Cecilia, D., and Gould, E. A. (1991). Nucleotide changes responsible for
loss of neuroinvasiveness in Japanese encephalitis virus neutraliza-
tion-resistant mutants. Virology 181, 70–77.
Chase, A. (1982). ‘‘Magic Shot: A Human and Scientific Account of Long
and Continuing Struggle to Eradicate Infectious Diseases by Vacci-
nation,’’ p.1. Morrow, New York.
Chen, Y., Maguire, T., Hileman, R. E., Fromm, J. R., Esko, J. D., Linhardt,
R. J., and Marks, R. M. (1997). Dengue virus infectivity depends on
envelope protein binding to target cell heparin sulfate. Nature Med.
3, 866–871.
Devereux, J., Haeberli, P., and Smithies, O. (1984). A comprehensive set
of sequence analysis programs for the VAX. Nucleic Acids Res. 12,
387–395.
Fields, B. N., and Greene, M. I. (1982). Genetic and molecular mecha-
nisms of viral pathogenesis: Implications for prevention and treat-
ment. Nature 300, 19–23.
Gao, G. F., Hussain, M. H. Reid, H. W., and Gould, E. A. (1994). Identi-
fication of naturally occurring monoclonal antibody escape variants
of louping ill virus. J. Gen. Virol. 75, 609–614.
Guirakhoo, F., Heinz, F. X., Mandl, C. W., Holzmann, H., and Kunz, C.
(1991). Fusion activity of flaviviruses: comparison of mature and
immature (prM-containing) tick-borne encephalitis virions. J. Gen.
Virol. 72, 1323–1329.
Hasegawa, H., Yoshida M., Shiosaka, T., Fujita, S., and Kobayashi, Y.
(1992). Mutation in the envelope protein of Japanese encephalitis
virus affect entry into cultured cells and virulence in mice. Virology
191, 158–165.
Heinz, F. X., Auer, G., Stiasny, K., Holzmann, H., Mandl, C., Guirakhoo, F.,
and Kunz, C. (1994). The interactions of the flavivirus envelope pro-
teins: implications for virus entry and release. Arch. Virol. 9, 339–348.
Hiramatsu, K., Tadano, M., Men, R., and Lai, C. J. (1996). Mutation
analysis of a neutralization epitope on the dengue type 2 virus
envelope protein: Monoclonal antibody resistant DEN2/DEN4 chime-
ras exhibit reduced mouse neurovirulence. Virology 224, 437–445.
Holzmann, H., Mandl, C. W., Guirakhoo, F., Heinz, F. X., and Kunz, C.
(1989). Characterization of antigenic variants of tick-borne encepha-
litis virus selected with neutralizing monoclonal antibodies. J. Gen.
Virol. 70, 219–222.
Huang, C.H. (1982). Studies of Japanese encephalitis in China. Adv.
Virol. Res. 27, 71–101.
Jiang, W. R., Lowe, A., Higgs, S., Reid, H., and Gould, E. A. (1993). Single
amino acid codon changes detected in louping ill virus antibody-
resistance mutatants with reduced neurovirulence. J. Gen. Virol. 74,
931–935.
Lentz, T. L. (1990). The recognition event between virus and host cell
receptor: A target for antiviral agents. J. Gen. Virol. 71, 751–766.
Marianneau, P., Megret, F., Oliver, R., Morens, D. M., and Deubel, V.
(1996). Dengue 1 virus binding to the human hepatoma HepG2 and
simian Vero cell surfaces differs. J. Gen. Virol. 77, 2547–2554.
Middlemiss, D. N., and Frozard, J. R. (1983). 80 HDPAT discrimination
between subtypes of 5-HT1 recognition site. Eur. J. Pharmacol. 90,
151–153.
Mims, C. A. (1986). Virus receptors and cells tropism. J. Infect. 12,
199–203.
Monath, T. P. (1990). Flaviviruses. In ‘‘Virology’’ (B. N. Fields, D. M. Knipe
et al., Eds.) pp. 763–814. Raven Press, New York.
Ni, H., and Barrett, A. D. T. (1996). Analysis of molecular basis of high
neuro-invasiveness for mice of wild-type JE virus strain P3. J. Gen.
Virol. 77, 1449–1455.
Ni, H., Burns, N. J., Chang, G. J., Zhang, M. J., Wills, M. R., Trent, D. W.,
Sanders, P. G., and Barrett, A. D. T. (1994). Comparison of nucleotide
and deduced amino acid sequence of the 59 non-coding region and
structural protein genes of the wild-type Japanese encephalitis virus
strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75,
505–1510.
Norkin, L. C (1995). Virus receptors: Implications for pathogenesis and
the antiviral agents. Clin. Microbiol. Rev. 8, 293–315.
Paulson, J. C. (1985). Interaction of animal viruses with cell surface
receptors. In ‘‘The Receptors,’’ (P. M. Conn, Ed.) Vol. 2; pp. 131–219.
Academic Press, Orlando.
Queen, C. G., and Korn, L. J. (1984). A comprehensive sequence anal-
ysis program for the IBM personal computer. Nucleic Acids Res. 12,
581–599.
Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C., and Harrison, S. C. (1995).
The envelope glycoprotein from tick-borne encephalitis virus at 2 A
resolution. Nature 375, 291–298.
Sanchez, I. J., and Ruiz, B. H. (1996). A single nucleotide change in the
E protein of dengue 2 Mexican strain affects neurovirulence in mice.
J. Gen. Virol. 77, 2541–2545.
Westaway, E. G., Brinton, M. A., Gaidamovich, S. Y., Horzinek, M. C.,
Igarashi, A., Kaarianen, L., Lvov, D. K., Porterfield, J. S., Fussell, P. K.,
and Trent, D. W. (1985). Flaviviridae. Intervirology 24, 183–192.
Wills, M. R., Sil, B. K., Cao, J. X., and Barrett, A. D. T. (1992). Antigenic
characterization of the live attenuated Japanese encephalitis vaccine
virus SA14-14-2: A comparison with isolates of virus covering a wild
geographic area. Vaccine 10, 861–872.
World Health Organization. (1980). The global eradication of smallpox:
Final report of the global commission for the certification of smallpox
eradication. In ‘‘History of International Public Health,’’ No. 4. WHO,
Geneva.
36 NI AND BARRETT
